The aim of this study was to investigate the time-to-onset of drug-induced interstitial lung disease (DILD) following the administration of small molecule molecularly-targeted drugs via the use of the spontaneous adverse reaction reporting system of the Japanese Adverse Drug Event Report database. DILD datasets for afatinib, alectinib, bortezomib, crizotinib, dasatinib, erlotinib, everolimus, geˆtinib, imatinib, lapatinib, nilotinib, osimertinib, sorafenib, sunitinib, temsirolimus, and tofacitinib were used to calculate the median onset times of DILD and the Weibull distribution parameters, and to perform the hierarchical cluster analysis. The median onset times of DILD for afatinib, bortezomib, crizotinib, erlotinib, geˆtinib, and nilotinib were within one month. The median onset times of DILD for dasatinib, everolimus, lapatinib, osimertinib, and temsirolimus ranged from 1 to 2 months. The median onset times of the DILD for alectinib, imatinib, and tofacitinib ranged from 2 to 3 months. The median onset times of the DILD for sunitinib and sorafenib ranged from 8 to 9 months. Weibull distributions for these drugs when using the cluster analysis showed that there were 4 clusters. Cluster 1 described a subgroup with early to later onset DILD and early failure type proˆles or a random failure type proˆle. Cluster 2 exhibited early failure type proˆles or a random failure type proˆle with early onset DILD. Cluster 3 exhibited a random failure type proˆle or wear out failure type proˆles with later onset DILD. Cluster 4 exhibited an early failure type proˆle or a random failure type proˆle with the latest onset DILD.
INTRODUCTION
Drug-induced interstitial lung disease (DILD) can be caused by a variety of drugs including chemotherapeutic agents, antibiotics, antiarrhythmic drugs, and immunosuppressive agents. Up to 10％ of patients receiving chemotherapeutic agents have been reported to develop adverse drug reactions (ADRs) in their lungs. 1) The mechanisms of DILD that have been suggested include 1) induction of pulmonaryˆbrosis due to a direct toxic reaction to the drugs, 2) the drugs act as potential antigens or haptens that subsequently cause immune-mediated lung toxicity, and 3) the drugs cause phospholipidosis in alveolar macrophages and in type 2 cells. 2) One of the keys to the recent advances in cancer therapy has been the use molecularly-targeted agents. Previous studies have investigated factors related to the occurrence of DILD after the administration of molecularly-targeted drugs. These studies have examined epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), vascular endothelial growth factor receptor (VEGFR) TKI, platelet derived growth factor receptor (PDGFR) TKI, and the mammalian target of rapamycin (mTOR) inhibitor. 3 6) DILD is a commonly observed ADR that occurs after the administration of molecularlytargeted drugs. In Japan, a retrospective analysis found geˆtinib-induced ILD occurred in 3.5％ of the patients, while a prospective study reported that it occurred in 5.8％ of the patients. 7, 8) DILD incidence with erlotinib therapy in Japan has been reported to be 26.4％. 6, 9) Variations in the time-to-onset for ADRs have been shown to range from several minutes to months or even years after the beginning of treatment. In our previous study, we analyzed the adverse events information using the Japanese Adverse Drug Event Report (JADER) and found that the median time-toonset of DILD for geˆtinib and for erlotinib were 25 and 22 d, respectively, while the time-to-onset for imatinib was 133 d. 10) During theˆrst 4 weeks after treatment initiation, there was a clear increased risk of DILD associated with geˆtinib treatment. However, the risk of DILD associated with geˆtinib treatment appears to occur at greater than 4 weeks af-ter the initiation of the treatment. In addition, the clinical features of early onset cases are characterized by a rapid progression and a high mortality rate. 11) Among those who developed acute DILD, the mortality rate in the treated patients was 31.6％. 12) Thus, it is important to determine how the DILD occurrence varies over time during the administration of small molecule molecularly-targeted drug therapy.
The Pharmaceuticals and Medical Devices Agency (PMDA) has created and released a spontaneous ADR reporting system for the JADER database. This database, which consists of 4 data tables, includes the patient demographics information table (demo), the drug information table (drug), the adverse events table (reac), and the primary illness table (hist). The adverse events in reac are coded according to the terminology preferred by the Medical Dictionary for Regulatory Activities (MedDRA). 13) The lowest level term group for DILD includes many diŠerent syndromes (e.g., interstitial lungˆbrosis, interstitial pneumonia, pneumonia interstitial diŠuse, follicular bronchiolitis, etc.).
Many reports have recently highlighted the fact that the post-marketing spontaneous reporting database has proven to be a valuable resource for estimating the time-to-onset of ADRs when using a Weibull analysis. 14 19) The scale parameter of the Weibull distribution is used to determine the scale of the distribution function, with the scale parameter deˆned as 63.2 ％ of the lower-side of the Weibull distribution. Thus, when a larger value for the scale parameter is present, this stretches the distribution, while a smaller value for the scale parameter will shrink the data distribution. The shape parameter of the Weibull distribution can be used to deˆne a hazard without having to refer to a reference population. For example, if the shape parameter is less than 1 and the 95％ conˆdence interval (95％ CI) of the shape parameter is less than the value 1, the hazard is considered to have decreased over time (early failure type proˆle). If the shape parameter is equal to or nearly 1 and the 95％ CI of the shape parameter includes the value 1, the hazard is estimated to have been constant over time (random failure type proˆle). If the shape parameter is greater than 1 and the 95％ CI of the shape parameter excluded the value 1, the hazard is considered to have increased over time (wear out failure type proˆle).
Over time, the utilization of the principle of cluster analysis has expanded so that it is now used in multiple areas, such as bioinformatics, epidemiology and diagnostics. 20 23) Cluster analysis techniques have also been used to identify patterns. When grouping individuals into clusters, similarity between members of the same clusters is strong. In current study, I applied the cluster analysis in order to classify the time-to-onset of DILD after the administration of small molecule molecularly-targeted drugs. The aim of this study was to investigate the time-to-onset of DILD after the administration of small molecule molecularly-targeted drugs using JADER, and then determine and classify the diŠerences in the time-to-onset of DILD for these drugs.
MATERIALS AND METHODS
The JADER database from April 2004 to March 2017 was downloaded from the PMDA website. 24) The JADER database consists of four data tables: patient demographic information (demo), drug information (drug), adverse event and outcome informations (reac), and medical history information (hist). The demo (440485 cases), drug (2833811 cases) and reac (697424 cases) tables were integrated into the dataset for the time-to-onset using JMP 12.0 (SAS Institute Inc., Cary). It is known that duplicate report that exists in these tables has an impact on the evaluation and analysis. Therefore, in order to exclude the overlap of reported cases, the duplicate reports were removed based on each identiˆcation number. In addition, the blank and date that was not correctly described were excluded. Time-to-onset of DILD was calculated from the time of the patient's prescription to theˆrst occurrence of DILD. The datasets for the time-to-onset of DILD for afatinib, alectinib, bortezomib, crizotinib, dasatinib, erlotinib, everolimus, geˆtinib, imatinib, lapatinib, nilotinib, osimertinib, sorafenib, sunitinib, temsirolimus, and tofacitinib were then used to calculate the Weibull parameters. I postulated that cluster analysis could be applied for classifying the time-to-onset patterns of DILD following the administration of small molecule molecularly-targeted drugs. The object of this algorithm to classify the time-to-onset patterns of DILD that exhibit relevant diŠerences in the median onset time, the scale parameter and the shape parameter of Weibull distribution, and to compute a dendrogram that assembles these into a single tree. Cluster analysis was carried out using the median onset time, the scale parameter and the shape parameter. A hierarchical cluster analysis using Ward's method was utilized to generate a dendrogram for estimation of the number of likely clusters. The estimations for Weibull parameters and cluster analysis were performed using JMP 12.0. Statistical analysis was performed using the Steel-Dwass test on each pair. p values of less than 0.05 were considered to indicate statistical signiˆcance.
RESULTS
The median onset times of DILD for afatinib, bortezomib, crizotinib, erlotinib, geˆtinib, and nilotinib were within one month ( Table 1) . The median onset times of DILD for dasatinib, everolimus, lapatinib, osimertinib, and temsirolimus ranged from 1 to 2 month. The median onset times of the DILD for alectinib, imatinib, and tofacitinib ranged from 2 to 3 months. The median onset times of the DILD for sunitinib and sorafenib ranged from 8 to 9 months. The earliest median time-to-onset of DILD was 8 d for bortezomib. In contrast, the median time-to-onset for sorafenib was 262 d, which was 32.8 times longer than that for bortezomib. Comparisons of the median time-to-onset of DILD between sorafenib and all of the other drugs showed that sunitinib (247 d) and tofacitinib (65 d) were not signiˆcantly diŠerent. For sunitinib, the median time-to-onset of DILD was signiˆcantly longer than that of all drugs except for tofacitinib. The median time-to-onset of DILD for imatinib (93 d) was signiˆcantly longer than the medians for afatinib (26.5 d), bortezomib, crizotinib
, and temsirolimus (35 d). The median time-to-onset of DILD for alectinib (67 d) and everolimus were signiˆcantly longer than the medians for afatinib, bortezomib, crizotinib, erlotinib, geˆtinib, osimertinib, and temsirolimus. The median time-to-onset of DILD for lapatinib (53 d) was signiˆcantly longer than the medians for bortezomib, crizotinib, and erlotinib. The median timeto-onset of DILD for temsirolimus was signiˆcantly longer than the medians for bortezomib and erlotinib. In addition, the median time-to-onset of DILD for bortezomib was signiˆcantly shorter than the medians for afatinib, crizotinib, dasatinib (31.5 d), erlotinib, geˆtinib, and osimertinib.
The histograms of the DILD onset time for bortezomib, crizotinib, erlotinib, afatinib, geˆtinib, dasatinib, nilotinib, lapatinib, imatinib, and sorafenib demonstrate the early onset time proˆles, with the DILD then shown to decrease over time (F, D, O, E, I, K, J, N, P, and L in Fig. 1 ). Since the upper 95％ CI for the shape parameter was less than 1, the DILD onset time proˆles of these drugs were considered to be similar to the early failure type ( Table  2 ). The DILD onset time proˆles for temsirolimus, alectinib, tofacitinib, and sunitinib were classiˆed as the random failure type based on the 95％ CI of the shape parameter including the value 1 (C, B, H, and M in Fig. 1 ). The histograms of the DILD onset time for osimertinib and everolimus indicated there was a broad distribution (A and G in Fig. 1 ). The shape parameters for osimertinib and everolimus were categorized as the wear out failure type proˆle, as the 95％ CI exceeded 1. Figure 2 shows the hierarchical cluster analysis that generated the dendrogram for estimation of the 4 clusters. Cluster 1, which included bortezomib, nilotinib, dasatinib, lapatinib, tofacitinib, and imatinib, showed early failure type proˆles (bortezomib, nilotinib, dasatinib, lapatinib, and imatinib) or a random failure type proˆle (tofacitinib) with an early to later onset time. Cluster 2, which included erlotinib, geˆtinib, crizotinib, afatinib, and temsirolimus, exhibited early failure type proˆles (erlotinib, geˆtinib, crizotinib, and afatinib) or a random failure type proˆle (temsirolimus) with an early onset time. Cluster 3, which included osimertinib, everolimus, and alectinib, exhibited a random failure type proˆle (alectinib) or wear out failure type proles (everolimus and osimertinib) with a later onset time. Cluster 4, which included sorafenib and sunitinib, exhibited an early failure type proˆle (sorafenib) or a random failure type proˆle (sunitinib) with the latest onset time.
. Histograms and Fitting Curves for the Weibull Distribution of the DILD
(A) osimertinib, (B) alectinib, (C) temsirolimus, (D) crizotinib, (E) afatinib, (F) bortezomib, (G) everolimus, (H) tofacitinib, (I) geˆtinib, (J) nilotinib, (K) dasatinib, (L) sorafenib, (M) sunitinib, (N) lapatinib, (O) erlotinib, and (P) imatinib.
DISCUSSION
Currently there have been over 450 diŠerent drugs implicated as being involved in DILD. 2) Recently, there has been an increased amount of data on molecularly-targeted drugs that cause DILD, including EGFR TKI, anti-EGFR antibodies, mTOR inhibitors, Bcr-Abl TKI, and multi-kinase inhibitors. 25) In the current study, the median onset times of DILD for the 26S proteasome inhibitor (bortezomib), anaplastic lymphoma kinase (ALK) TKI (crizotinib), EGFR TKI (erlotinib and geˆtinib), ErbB family inhibitor (afatinib), and BcrAbl TKI (nilotinib) were within one month. The median onset times of DILD for Bcr-Abl TKI (dasatinib), mTOR inhibitor (everolimus and temsirolimus), ErbB family inhibitor (lapatinib), and EGFR TKI (osimertinib) ranged from 1 to 2 month. The median onset times of the DILD for ALK TKI (alectinib), Bcr-Abl TKI (imatinib), and Janus kinase (JAK) inhibitor (tofacitinib) ranged from 2 to 3 months. The median onset times of the DILD for the multiple receptor TKI, which included PDGFR inhibition and VEGFR inhibition (sunitinib and sorafenib), ranged from 8 to 9 months.
Weibull distributions for these drugs when using the cluster analysis showed that there were 4 clusters. Cluster 1 described a subgroup with early to later onset DILD (median onset time from 8 to 93 d and scale parameter from 19.0 to 203) and early failure type proˆles (increase in the hazard at an early stage followed by a decrease) or a random failure type proˆle (the hazard was estimated to be constant over time), which included the proteasome inhibitor (bortezomib), Bcr-Abl TKI (dasatinib, nilotinib, and imatinib), JAK inhibitor (tofacitinib), and ErbB family TKI (lapatinib). Cluster 2 described a subgroup with an early onset DILD (median onset time from 21 to 35 d and scale parameter from 34.7 to 49.3) and early failure type proˆles or a random failure type proˆle, which included EGFR TKI (erlotinib and geˆtinib), ALK TKI (crizotinib), ErbB family inhibitor (afatinib), and mTOR inhibitor (temsirolimus). Cluster 3 described a subgroup with a later onset time (median onset time from 34.5 to 67 d and a scale parameter from 44.7 to 102) and a random failure type proˆle or wear out failure type proˆles (the hazard was considered to increase over time), which included the EGFR TKI (osimertinib), mTOR inhibitor (everolimus), and ALK TKI (alectinib). Cluster 4 was described as a subgroup with the latest onset DILD (median onset time from 247 to 262 d and scale parameter ranging from 308 to 333) and an early failure type proˆle or a random failure type proˆle, which included the multiple receptor TKI with both PDGFR and VEGFR inhibition (sunitinib and sorafenib). Thus, it appears that the diŠerences observed between the clusters may be indicative of the mechanism of action for some of these small molecule molecularly-targeted drugs. Based on theseˆndings, further research will need to be undertaken that examines the association between the mechanism of action for these drugs and the time-to-onset of the DILD. However, any subsequent research will need to take the following reportedˆndings into consideration when attempting to draw conclusions on the mechanism of action and time-to-onset. Abe et al. reported that any interpretation of data from small sample sizes (notably, less than 100 case reports) should be performed cautiously. 17) Thus, it should be noted that there were less than 100 case reports for ALK TKI (alectinib), Bcr-Abl TKI (dasatinib and nilotinib), ErbB family TKI (lapatinib), EGFR TKI (osimertinib), and JAK inhibitor (tofacitinib) found in JADER in our current study. Therefore, due to the small number of samples, the variance of the regression line that was estimated by the Weibull analysis would be increased. As a result, theˆndings for these drugs may not be conclusive. Secondly, the fact that the time-to-onset of the DILD was only performed using 16 small molecule molecularly-targeted drugs in this study needs to be taken into consideration. Even so, there has been a recent increase in the amount of data being reported on molecularly-targeted drugs that cause DILD, with a few of these cases reporting on new small molecule molecularly-targeted drugs such as bosutinib, vandetanib, lenvatinib, nintedanib, ceritinib, ibrutinib, and ruxolitinib in the JADER database. Finally, while post-marketing spontaneous reporting of suspected ADRs has proven to be a valuable resource, it should be noted that spontaneous reporting databases, such as the JADER, are subject to various biases that include over-reporting, under-reporting, missing data, exclusion of healthy individuals, lack of denominator, and confounding factors. In addition, there has yet to be any information provided on the total number of patients who have been treated with these drugs. Therefore, careful attention needs to be paid to any interpretation of results from the JADER database. Furthermore, associations between the physicochemical and/or other properties of the small molecule molecularly-targeted drugs and the time-to-onset of the DILD will need to be examined in more detail in future studies.
In conclusion, results of the current study showed that EGFR TKI, ErbB family inhibitor, proteasome inhibitor, and mTOR inhibitor were associated with an early onset of DILD within 1 to 2 months of the initial administration. In contrast, the multiple receptor tyrosine kinase inhibitors, including PDGFR and VEGFR inhibition, exhibited the latest onset of DILD with onset times over 8 months. However, the onset of DILD for Bcr-Abl TKI exhibited wide variations (ranging from 14 to 93 d) with an early failure type proˆle. Theˆndings suggest that the mechanism of action for the time-to-onset of the DILD appears to be associated with certain small molecule molecularly-targeted drugs. Furthermore, the current study demonstrated the range of times that DILD may be found and the most likely time period that DILD will actually occur in patients after the administration of small molecule molecularly-targeted drugs, which is of great importance. As a result, thesê ndings may potentially lead to a more concrete pharmacovigilance.
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